ABSeed

ABSeed is a Sao Paulo-based venture firm with a sharp B2B SaaS thesis, deploying $250k-$1M cheques at Seed and Series A into companies that provide essential software infrastructure for industries including healthcare. The firm’s portfolio reflects a disciplined preference for vertical SaaS with measurable enterprise traction rather than consumer plays. For founders, ABSeed is best understood as a category-focused early lead for B2B health software in Brazil and Portuguese-speaking markets. The right founder is a Brazilian operator building enterprise health IT, RCM, EHR, clinic management software, or AI-enabled clinical workflow tools with paid pilots converting to multi-year contracts. Founders running consumer wellness, asset-heavy clinic models, or biotech plays should not approach. The cleanest entry path is via an ABSeed portfolio CEO, the Sao Paulo SaaS founder community, or warm introductions from Brazilian seed funds that frequently co-invest (Darwin, Igah’s earlier book, Maya Capital). In the pitch, lead with ARR, gross retention, sales productivity, and a credible Series A narrative that names likely Brazilian and international leads. AI claims should be grounded in commercial deployment rather than model novelty; ABSeed values software fundamentals over technology fashion. Caveats: as a small-cheque seed fund, ABSeed’s reserves and follow-on capacity are limited, so founders should plan to syndicate with Series A leads early. The firm’s brand carries solid weight in Brazilian SaaS and modest weight internationally, so pair ABSeed with international co-leads as you scale. Brazilian macro and currency volatility, plus payer concentration dynamics, will be discussed during diligence. Confirm reserves and follow-on policy explicitly during initial conversations, and request a recent deal sheet to verify health-specific pacing.